March 28, 2022 Pre-Market Earnings Report: JEF, SAIC, BCLI, VERO, VIOT

JThe following companies are expected to report earnings before the market opens on 03/28/2022. See our results calendar for a full list of expected results releases.
Jefferies Financial Group Inc. (JEF) reports for the quarter ending Feb. 28, 2022. The financial services company’s consensus earnings-per-share forecast from 2 analysts who track the stock is $0.92. This value represents a decrease of 57.01% compared to the same quarter last year. JEF missed consensus earnings per share in the 4th calendar quarter of 2021 by -2.86%. Zacks Investment Research reports that the 2022 P/E ratio for JEF is 8.93 versus an industry ratio of 9.60.
INTERNATIONAL SOCIETY OF SCIENTIFIC APPLICATIONS (SAIC) reports for the quarter ending Jan. 31, 2022. The information technology services company‘s consensus earnings per share forecast from the 7 analysts who track the stock is $1.18. This value represents a decrease of 29.34% compared to the same quarter last year. Over the past year, SAIC has exceeded expectations every quarter. The highest was in the 4th calendar quarter where they beat consensus by 27.59%. Zacks Investment Research reports that the 2022 price-to-earnings ratio for SAIC is 13.07 versus an industry ratio of 46.80.
Brainstorming Cell Therapeutics Inc. (BCLI) reports for the quarter ending Dec. 31, 2021. The consensus earnings per share forecast for the biomedical company (gene) from the top analyst tracking the stock is -$0.20. This value represents an increase of 45.95% compared to the same quarter last year. Over the past year, BCLI has exceeded expectations every quarter. The highest was in the 3rd calendar quarter where they beat consensus by 28.57%. The “days to cover” for this stock exceeds 13 days. Zacks Investment Research reports that the 2021 P/E ratio for BCLI is -4.96 versus an industry ratio of -16.30, implying that they will have higher earnings growth than their competitors in the same industry.
Venus Concept Inc. (VERO) reports for the quarter ending Dec. 31, 2021. The medical devices company’s consensus earnings-per-share forecast from the top analyst tracking the stock is -$0.12. This value represents an increase of 45.45% compared to the same quarter last year. Zacks Investment Research reports that the 2021 price-to-earnings ratio for VERO is -2.71 versus an industry ratio of -16.40, implying that they will have higher earnings growth than their competitors in the same industry.
Viomi Technology Co.,Ltd (VIOT) reports for the quarter ending Dec. 31, 2021. The internet services company’s consensus earnings-per-share forecast from the top analyst tracking the stock is $0.02. This value represents a decrease of 91.67% compared to the same quarter last year. VIOT missed consensus earnings per share in the 3rd calendar quarter of 2021 by -131.25%. Zacks Investment Research reports that the 2021 price-to-earnings ratio for VIOT is 12.33 versus an industry ratio of -3.10, implying that they will have higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.